Mid-Tier Japanese Pharma See Flurry Of Licensing Activity Ahead Of Earnings Season
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's mid-tier pharma have had a fruitful week during and following the BioJapan partnering conference in Yokohama, announcing a number of deals with Japanese and Western biotechs as they continue to broaden their reach outside of Japan